Search

European policymakers are largely to blame for the sorry state of innovation in Europe, according Microsoft’s chief research and strategy officer.

The US biotechnology industry has gone through more than three years of sustained IPO financings, but that news isn’t all rosy for the industry.

The technology funding gap has long been with us, but in drug discovery it has widened into a chasm.

IPOs are up in the year to date. But the value of these deals is down. Rather than cashing out, VCs are getting a ticket to stay on for a white-knuckle ride.

UK scientists are claiming a significant advance in hydrogen storage that they say could remove a key barrier to using fuel cells in cars.